Lpl Financial LLC Pds Biotechnology Corp Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Lpl Financial LLC holds 10,412 shares of PDSB stock, worth $21,969. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,412

Previous 10,412 -0.0%

Holding current value

$21,969

Previous $30,000 30.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$2.55 - $4.02 $301,035 - $474,573	-118,053 Reduced 91.9%	10,412 $30,000
Q1 2024 May 10, 2024	SELL	$3.85 - $6.59 $11,788 - $20,178	-3,062 Reduced 2.33%	128,465 $508,000
Q4 2023 Feb 14, 2024	SELL	$3.95 - $6.58 $407,837 - $679,385	-103,250 Reduced 43.98%	131,527 $653,000
Q3 2023 Nov 13, 2023	SELL	$4.8 - $6.4 $339,288 - $452,384	-70,685 Reduced 23.14%	234,777 $1.19 Million
Q2 2023 Jul 31, 2023	SELL	$5.03 - $9.9 $114,608 - $225,571	-22,785 Reduced 6.94%	305,462 $1.54 Million
Q1 2023 May 10, 2023	SELL	$5.68 - $11.99 $285,209 - $602,053	-50,213 Reduced 13.27%	328,247 $2.02 Million
Q4 2022 Feb 07, 2023	SELL	$3.28 - $13.2 $376,448 - $1.51 Million	-114,771 Reduced 23.27%	378,460 $5 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $887,231 - $1.73 Million	298,731 Added 153.59%	493,231 $1.47 Million
Q2 2022 Aug 12, 2022	BUY	$3.05 - $6.68 $593,225 - $1.3 Million	194,500 New	194,500 $710,000
Q4 2021 Feb 14, 2022	SELL	$7.76 - $14.35 $352,583 - $652,006	-45,436 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.33 - $17.08 $52,378 - $95,887	-5,614 Reduced 11.0%	45,436 $677,000
Q2 2021 Aug 13, 2021	BUY	$4.35 - $12.86 $222,067 - $656,503	51,050 New	51,050 $641,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

4.32M

Call Options Held

253K

Put Options Held

70.4K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $60M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Pds Biotechnology Corp Transaction History